Dublin, Feb. 05, 2020 (GLOBE NEWSWIRE) -- The "3rd Annual Next-Gen Immuno-Oncology Congress" conference has been added to ResearchAndMarkets.com's offering.

This congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, monoclonal antibody & Immune Checkpoint Inhibitors.

The congress would also focus on various combination strategies, brain-storming on cancer biomarker and vaccine research, collaborating on pre-clinical and translational immune-oncology developments, and personalized cancer immunotherapy

Key Highlights

• Immune Checkpoint Inhibitors and Combinations
• Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
• Monoclonal Antibody & Cellular Therapy
• Neoantigens in personalized Cancer Immunotherapy
• Biomarkers and Cancer Vaccines
• Developments in CAR-T Cellular Therapy
• Oncolytic Viral Therapy & Personalized Medicine
• Engineering Cellular Therapies Beyond Traditional Tumor Antigens
• Combination Therapies in I/O

What makes I-O transformative? Innovative approaches in patient selection, use of combinations, and sequencing of therapies lead to more patients benefitting from I-O therapy, expanding its potential impact and this also makes it more promising - from the basics of immunotherapies to the latest research results.

The rapid development of immuno-oncology (I-O) therapies has transformed the treatment landscape and brightened the long-term outlook for many patients with advanced cancer.

Why Attend?

• Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
• Find out new case studies of immune-oncology projects in development
• Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
• Explore the latest platforms and technologies on the market for development
• Discuss the best tool for your research in immune-oncology
• Share your work and achievements with your industry peers in the Poster Sessions

Speakers

• Dave Wustrow: Senior VP Discovery and Preclinical Development, RAPT Therapeutics
• Darrell Borger: Associate Director, Translational Sciences, ODDU, Takeda
• Robert Petit: Chief Scientific Officer, Carisma Therapeutics
• Nuzhat Pathan: Director, Early Development, Translational and Immuno-Oncology, Pfizer
• Philip Arlen: Chief Scientific Officer, Senior Vice President, Diverse Biotech
• Nathaniel Wang: Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson
• Shailesh Maingi: Founder and CEO, Kineticos Life Sciences
• Soldano Ferrone: Professor of Surgery, Harvard University, USA

For more information about this conference visit https://www.researchandmarkets.com/r/9vcsad

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.